Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 21, 2009, Pages 7487-7492

  Tanaka, Michinori ^a   Kajiwara, Kazumi ^a,b   Tokiwa, Rei ^a,b   Watanabe, Kentaro ^a   Ohno, Hiroaki ^a   Tsutsumi, Hiroko ^c   Hata, Yoji ^c   Izumi, Kazuki ^a   Kodama, Eiichi ^a   Matsuoka, Masao ^a   Oishi, Shinya ^a   Fujii, Nobutaka ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c Gekkeikan Sake Company Ltd   (Japan)

Author keywords

Bioorganic synthesis; End capped peptide; Fusion inhibitor; HIV 1

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAP BINDING PROTEIN; PEPTIDE; RECOMBINANT PROTEIN; CYSTEINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HYBRID PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PROTEIN CLEAVAGE; SYNTHESIS; AMINO ACID SEQUENCE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR GENETICS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CYSTEINE; HIV FUSION INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; RECOMBINANT FUSION PROTEINS;

EID: 72149092530     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.09.015     Document Type: Article

References (32)

1. For reviews, see: (a) Frokjaer, S.; Otzen, D. E. Nat. Rev. Drug Disc. 2005, 4, 298;
2. (b) Leader, B.; Baca, Q, J.: Golan, D. E. Nat. Rev. Drug Disc. 2008, 7, 21.
3. (a) Andersson, L.; Blomberg, L.; Flegel. M.; Lepsa, L.; Nilsson, B.; Verlander, M. Biopolymers 2000, 5, 227;
4. (b) Bray, B. L. Nat. Rev. Drug Disc. 2003, 2, 587.
5. Dingermann, T. Biotechnol. J. 2008, 3, 90.
6. For recent reviews on the preparation of peptides and proteins having nonproteinogenic amino acid(s) or post-translational modification, see: (a) Muralidharan. V.; Muir, T. W. Nat. Methods 2006, 3, 429;
7. (b) Bennett, C. S.; Wong, C. H. Chem. Soc. Rev. 2007, 36,1227;
8. Ohta, A; Yamagishi, Y.: Suga, H. Curr. Opin. Chem. Biol. 2008, 12, 159.
9. (a) Stark, G. R. Methods Enzymol. 1977, 47, 129;
10. (b) Nakagawa, S.; Tamakashi, Y.; Hamana, T.: Kawase, M.; Taketomi, S.; Ishibashi, Y.; Nishimura. O.; Fukuda, T. J. Am. Chem. Soc. 1994, 116, 5513;
11. Nishimura, O.; Moriya, T.; Suenaga, M.; Tanaka, Y.; Itoh, T.; Koyama, N.; Fujii, R.; Hinuma, S.; Kitada, C.; Fujino, M. Chem. Pharm. Bull. 1998, 46, 1490;
12. Yang, Y.; Wu, J.; Watson, J. T. J. Am. Chem. Soc. 1998, 120, 5834;
13. (e) Suenaga, M.; Itoh. T.; Miwa, M.; Koyama, N.; Hinuma. S.; Kitada, C.; Nishimura, O.; Fujino, M. J. Chem. Soc., Perkin Trans. 1 2000,1183;
14. (f) Itoh, T.; Miwa, M.; Suenaga, M.; Ohtaki, T.: Kitada, C.; Nishimura, O.; Fujino, M. J. Chem. Soc. Perkin Trans. 1 2000, 1333;
15. (g) Nishimura, O.; Suenaga, M.: Yamada, T.; Itoh, T.: Koyama, N.; Wakimasu. M.; Ohtaki, T.; Kitada, C.; Fujino, M. J. Chem. Soc., Perkin Trans. 1 2001, 1748;
16. (h) Qi, J.: Wu. J.; Somkuti, G. A.; Watson, J. T. Biochemistry 2001, 40, 4531.
17. (a) Wu, J.; Watson, J. T. Anal. Biochem. 1998, 258, 268:
18. (b) Tang, H. Y.: Speicher, D. W. Anal. Biochem. 2004, 334, 48.
19. Hayashi, Y.; Takayama. K.; Suehisa, Y.; Fujita, T.; Nguyen. J. T.; Futaki, S.; Yamamoto, A.; Kiso, Y. Bioorg. Med. Chem. Lett. 2007, 17, 5129.
20. Other side reactions including dimerization of the peptides by disulfide bond formation were also observed.
21. The cyclic imide formation with concomitant peptide bond cleavage in neutral and basic conditions was previously reported: (a) Geiger, T.: Clarke, S. J. Biol. Chem. 1987, 262, 785;
22. (b) Patel, K.; Borchardt, R. T. Pharm. Res. 1990, 7, 787.
23. The ε-lactam formation accompanying amide bond cleavage was previously reported: (a) Takenawa, T.; Oda, Y.; Ishihama, Y.; Iwakura, M. J. Biochem. 1998. 123, 1137;
24. (b) Ishihama, Y.; Ito, O.; Oda, Y.; Takenawa, T.; Iwakura, M. Tetrahedron Lett. 1999, 40, 3415.
25. A small amount of a β-elimination product was observed under the various cleavage conditions examined.
26. Otaka, A.; Nakamura, M.; Nameki, D.; Kodama, E.; Uchiyama, S.; Nakamura, S.; Nakano, H.; Tamamura, H.: Kobayashi, Y.; Matsuoka, M.; Fujii, N. Angew. Chem., Int. Ed. 2002, 41, 2937.
27. Only partial S-cyanylations of two Cys residues in thioredoxin were observed. This was also verified by the recovery of C-termlnal capped thioredoxin 24a, b after basic treatment in the next step.
28. Peptides 20a, b from 22a, b were identical to the authentic samples, which were obtained by the cleavage reaction of the synthetic peptides.
29. Cytotoxicity of peptides 20a, b was not observed even at 10 uM in MAGI assay.
30. The presence of a hydrolyzed ring-opening product indicates that the degradation presumably began with hydrolysis of the C-terminal aspartimide, Ref. 9.
31. (a) Kodama, E. I.; Kohgo, S.; Kitano, K.; Machida, H.; Gatanaga, H.; Shigeta, S.; Matsuoka, M.; Ohrui, H.; Mitsuya, H. Antimlcrob. Agents Chemother. 2001, 45. 1539;
32. (b) Maeda, Y.; Venzon, D. J.; Mitsuya, H. J. Infect. Dis. 1998, 177, 1207.